 Anixa Biosciences, Inc. NASDAQ: ANIX, a biotechnology company focused on the treatment and prevention of cancer and infectious diseases, today announced that it and partner OntoChem have identified additional candidates through their in silico screening study. In addition to four compounds that target an endoribonuclease also known as Non-Structural Protein-15, or NSP-15 and one additional core compound that targets the main protease Mpro of the virus, Anixa and OntoChem have identified 26 additional compounds targeting Mpro. 